Lilly Maps Out China Strategy
This article was originally published in PharmAsia News
Last year, even as the worldwide pharmaceutical market growth slowed down to 3.8 percent, China powered ahead with a 15 percent increase. Eli Lilly's Chairman and CEO, Sidney Taurel, revealed that the company's business in China grew by 28 percent, which greatly fueled the overall corporate global performance. China Lilly is shifting its strategy from a FIPCO (Fully Integrated Pharmaceutical Company) model to FIPNET (Fully Integrated Pharmaceutical Network) model, which emphasizes collaboration rather than acquisition. The MNC has pumped investment into its China office as well as three local enterprises in Shanghai. Lilly China is exploring opportunities in community hospitals and will participate in drug tenders called by such organizations. (Click here for more - Chinese Language)
You may also be interested in...
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.
Market Intel: Why Telehealth, Digital Therapies Will Provide Mental Health Support Beyond COVID-19 Crisis
In this second part of a two-part series focusing on mental health tech, Medtech Insight highlights behavioral digital health companies that have attracted investors’ attention. Part one focused on transcranial magnetic stimulation.